Fair prices for ATTR-CM treatments assessed

The Institute for Clinical and Economic Review (ICER) has posted its revised Evidence Report assessing the comparative clinical effectiveness of three medicines for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM).

Pfizer’s (NYSE: PFE) Vyndamax/Vyndaqel (tafamidis), BridgeBio Pharma’s (Nasdaq: BBIO) acoramidis and Alnylam Pharmaceuticals’ (Nasdaq; ALNY) Amvuttra (vutrisiran) are the medicines in question.

While the Pfizer drug has been approved by the US Food and Drug Administration (FDA) for ATTR-CM and has a list price of approximately $268,000 per year, the other two have not, and the manufacturers have not announced US prices for each therapy if approved.